TrialSignal
Clinical trial intelligence report
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Bio-Manguinhos/Fiocruz COVID-19 (mRNA) Vaccine Booster in Healthy Adults
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT07640308-Jul 28, 2026
NCT ID
NCT07640308
Status
NOT_YET_RECRUITING
Phase
PHASE1
Sponsor
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Executive brief
Investment-Ready Snapshot
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Bio-Manguinhos/Fiocruz COVID-19 (mRNA) Vaccine Booster in Healthy Adults is a PHASE1 clinical asset sponsored by The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) in Severe Acute Respiratory Syndrome (SARS-CoV-2 Virus). SEO and diligence focus: Grupo 1
dose 25 μg, Group 2
50 μg dose, Group 3
100 μg, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT07640308
Indication
Severe Acute Respiratory Syndrome (SARS-CoV-2 Virus)
Modality
RNA therapy
Target
Grupo 1 - dose 25 μg, Group 2 - 50 μg dose, Group 3 - 100 μg
Intervention
Grupo 1 - dose 25 μg, Group 2 - 50 μg dose, Group 3 - 100 μg
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.